Frontlight ResearchEarly access
CompletedPhase 1/2
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
Key facts
- Who runs it
- ModernaTX, Inc.
- Where
- Beachwood, Beverly Hills, Birmingham, Boston, Cedar Park, Fort Worth, Grand Island, Houston, Lake City, Lenexa, Miami, New Orleans, Newport News, Newton, Norfolk, Raleigh, Rochester, San Antonio, San Diego, Seattle, Southfield, Tomball, and Tucson, United StatesSee the 23 sites
- Trial code
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 303 people enrolled
- Started
- 6 Sept 2023
- Ended
- 25 Apr 2025
- Type of study
- Interventional, 4 groups
- Treatments tested
- mRNA-1608
- BEXSERO
- Record updated
- 8 May 2026
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Participant has a diagnosis of genital HSV-2 infection for at least 1 year before the Screening Visit
- Seropositive for HSV-2 as determined by Western Blot
- Participant has a history of recurrent genital herpes defined as at least 3 and no more than 9 reported genital herpes recurrences in the 12 months preceding the Screening Visit, or if currently on suppressive therapy, prior to initiation of suppressive therapy
- Willing to refrain from taking suppressive antiviral therapy from the Screening Visit until the end of the study
- Willing to refrain from the use of episodic antiviral therapy during the three 28-day anogenital swabbing periods. Episodic therapy may be used outside the three 28-day swabbing periods
- For female participants of childbearing potential: negative pregnancy test, adequate contraception, and not currently breastfeeding
Who cannot take part
- Prior immunization with a vaccine containing HSV antigens
- Previously received BEXSERO or other vaccine to prevent serogroup B meningococcal disease (also known as meningitis B)
- Has received or plans to receive any licensed or authorized vaccine, including COVID-19 vaccines, ≤ 28 days prior to the first study injection (Day 1), or plans to receive a licensed or authorized vaccine within 28 days before or after study injection with the exception of licensed influenza vaccines, which may be received more than 14 days before or after any study injection; Note: Other inclusion and exclusion criteria may apply
- History of any form of ocular HSV infection, HSV-related erythema multiforme, or HSV-related neurological complications
- History of genital HSV-1 infection
- History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) types 1 or 2 (HIV-1, HIV-2)
- Reported history of anaphylaxis or severe hypersensitivity reaction after receipt of any mRNA vaccine(s) or any components of the mRNA vaccines
- History of allergic disease or reactions likely to be exacerbated by any component of BEXSERO vaccine
Where in United States
- Velocity Clinical Research, ClevelandBeachwood, United States
- Cedars-Sinai Medical Center/Carbon HealthBeverly Hills, United States
- Accel Clinical Sites Network - Cahaba Medical CareBirmingham, United States
- Fenway HealthBoston, United States
- Velocity Clinical Research - AustinCedar Park, United States
- Helios CR Inc - Fort WorthFort Worth, United States
- Velocity Clinical ResearchGrand Island, United States
- DM Clinical ResearchHouston, United States
- Multi-Specialty Research Associates, Inc.Lake City, United States
- Johnson County Clin-Trials (JCCT)Lenexa, United States
- Suncoast Research Associates, LLCMiami, United States
- Research WorksNew Orleans, United States
- Health Research of Hampton RoadsNewport News, United States
- Alliance for Multispecialty Research, LLCNewton, United States
- Velocity Clinical ResearchNorfolk, United States
- M3 Wake Research, Inc.Raleigh, United States
- Rochester Clinical ResearchRochester, United States
- Sun Research InstituteSan Antonio, United States
- Acclaim Clinical ResearchSan Diego, United States
- University of Washington Virology Research ClinicSeattle, United States
- DM Clinical ResearchSouthfield, United States
- DM Clinical ResearchTomball, United States
- Noble Clinical ResearchTucson, United States
About the trial
What the trial wants to find out
The purpose of this study is to generate safety and immunogenicity data and establish a proof-of-concept of clinical benefit of the mRNA-1608 vaccine candidate.
The 4 groups in the trial
- mRNA-1608 Dose ATreatment being tested
Participants will receive 2 intramuscular (IM) injections of mRNA-1608 at Dose Level A, each dose administered at 0 and 2 months (Day 1 and Day 57).
Treatment: mRNA-1608
- mRNA-1608 Dose BTreatment being tested
Participants will receive 2 IM injections of mRNA-1608 at Dose Level B, each dose administered at 0 and 2 months (Day 1 and Day 57).
Treatment: mRNA-1608
- mRNA-1608 Dose CTreatment being tested
Participants will receive 2 IM injections of mRNA-1608 at Dose Level C, each dose administered at 0 and 2 months (Day 1 and Day 57).
Treatment: mRNA-1608
- BEXSEROOther group
Participants will receive 2 IM injections of BEXSERO, each dose administered at 0 and 2 months (Day 1 and Day 57).
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
- Record updated
- 8 May 2026